Celldex Therapeutics Inc’s recently made public that its SVP & GENERAL COUNSEL Jimenez Freddy A. unloaded Company’s shares for reported $0.12 million on Dec 04 ’25. In the deal valued at $29.09 per share,4,166 shares were sold. As a result of this transaction, Jimenez Freddy A. now holds 30,796 shares worth roughly $0.81 million.
Then, FREDDY A JIMENEZ bought 4,166 shares, generating $121,210 in total proceeds.
Before that, Wright Richard M. sold 49,298 shares. Celldex Therapeutics Inc shares valued at $1,183,177 were divested by the Former Officer at a price of $24.00 per share. As a result of the transaction, Wright Richard M. now holds 20,833 shares, worth roughly $0.55 million.
Mizuho initiated its Celldex Therapeutics Inc [CLDX] rating to an Outperform in a research note published on October 21, 2025; the price target was $48. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in mid October with a ‘”an Underweight”‘ rating. Canaccord Genuity began covering CLDX with “Buy” recommendation on April 28, 2025. Morgan Stanley started covering the stock on March 20, 2025. It rated CLDX as “an Overweight”.
Price Performance Review of CLDX
On Tuesday, Celldex Therapeutics Inc [NASDAQ:CLDX] saw its stock jump 1.54% to $26.43. Over the last five days, the stock has lost -3.08%. Celldex Therapeutics Inc shares have risen nearly 3.04% since the year began. Nevertheless, the stocks have risen 4.59% over the past one year. While a 52-week high of $30.50 was reached on 12/08/25, a 52-week low of $14.40 was recorded on 04/09/25.
Levels Of Support And Resistance For CLDX Stock
The 24-hour chart illustrates a support level at 25.81, which if violated will result in even more drops to 25.20. On the upside, there is a resistance level at 26.77. A further resistance level may holdings at 27.12.
How much short interest is there in Celldex Therapeutics Inc?
A steep rise in short interest was recorded in Celldex Therapeutics Inc stocks on 2025-12-15, dropping by -1.98 million shares to a total of 6.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 8.85 million shares. There was a decline of -28.84%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 13, 2025 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $44 price target.
